Zentalis Pharmaceuticals (ZNTL) Receivables (2019 - 2024)

Zentalis Pharmaceuticals' Receivables history runs 4 years deep, the most recent figure standing at $5.0 million for Q4 2024.

• In Q4 2024, Receivables changed N/A year-over-year to $5.0 million; the TTM figure through Dec 2024 stood at $5.0 million (changed N/A YoY), while the FY2024 annual figure was $5.0 million, changed N/A from the prior year.
• Receivables for Q4 2024 stood at $5.0 million, up from $2.4 million in the prior quarter.
• The five-year high for Receivables was $82.1 million in Q1 2020, with the low at $5000.0 in Q2 2021.
• The 3-year median for Receivables is $2.4 million (2021), against an average of $13.9 million.
• Peak annual rise in Receivables reached 470.02% in 2021, while the deepest fall reached 97.11% in 2021.
• Zentalis Pharmaceuticals' Receivables stood at $417000.0 in 2020, then jumped by 470.02% to $2.4 million in 2021, then soared by 110.35% to $5.0 million in 2024.
• Business Quant data shows ZNTL's Receivables at $5.0 million in Q4 2024, $2.4 million in Q4 2021, and $3.0 million in Q3 2021.